Anna Åleskog

566 total citations
28 papers, 434 citations indexed

About

Anna Åleskog is a scholar working on Genetics, Molecular Biology and Hematology. According to data from OpenAlex, Anna Åleskog has authored 28 papers receiving a total of 434 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Genetics, 12 papers in Molecular Biology and 9 papers in Hematology. Recurrent topics in Anna Åleskog's work include Chronic Lymphocytic Leukemia Research (15 papers), Lymphoma Diagnosis and Treatment (7 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Anna Åleskog is often cited by papers focused on Chronic Lymphocytic Leukemia Research (15 papers), Lymphoma Diagnosis and Treatment (7 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Anna Åleskog collaborates with scholars based in Sweden, Germany and Denmark. Anna Åleskog's co-authors include Richard Rosenquist, Gerard Tobin, Elin Lindhagen, Rolf Larsson, Christer Sundström, Göran Roos, Martin Höglund, Karin Karlsson, Ulf Thunberg and Peter Nygren and has published in prestigious journals such as Blood, Biochemical Pharmacology and Cancer Letters.

In The Last Decade

Anna Åleskog

28 papers receiving 424 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna Åleskog Sweden	13	156	153	109	95	81	28	434
R G Wickremasinghe United Kingdom	16	299 1.9×	109 0.7×	92 0.8×	42 0.4×	81 1.0×	25	537
Isha Kapoor India	13	376 2.4×	107 0.7×	141 1.3×	83 0.9×	84 1.0×	25	569
Lesley A. Mathews Griner United States	11	273 1.8×	43 0.3×	158 1.4×	58 0.6×	84 1.0×	18	514
Anna Wolska Poland	13	166 1.1×	62 0.4×	148 1.4×	46 0.5×	75 0.9×	29	512
Marie Sébert France	13	281 1.8×	116 0.8×	123 1.1×	38 0.4×	313 3.9×	47	593
Chiara Cavallini Italy	14	176 1.1×	65 0.4×	106 1.0×	51 0.5×	29 0.4×	20	408
Angelo Messina Italy	16	258 1.7×	55 0.4×	402 3.7×	96 1.0×	72 0.9×	26	773
Lijian Yu United States	9	201 1.3×	194 1.3×	87 0.8×	124 1.3×	84 1.0×	11	433
Shashi Mehta United States	11	224 1.4×	44 0.3×	147 1.3×	49 0.5×	36 0.4×	32	619
A. Keith Stewart United States	10	205 1.3×	32 0.2×	132 1.2×	44 0.5×	134 1.7×	17	419

Countries citing papers authored by Anna Åleskog

Since Specialization

Citations

This map shows the geographic impact of Anna Åleskog's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Åleskog with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Åleskog more than expected).

Fields of papers citing papers by Anna Åleskog

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Åleskog. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Åleskog. The network helps show where Anna Åleskog may publish in the future.

Co-authorship network of co-authors of Anna Åleskog

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Åleskog. A scholar is included among the top collaborators of Anna Åleskog based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Åleskog. Anna Åleskog is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Haglund, Caroline, Anna Åleskog, Peter Nygren, et al.. (2011). In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues. Cancer Chemotherapy and Pharmacology. 69(3). 697–707. 27 indexed citations

Gréen, Henrik, Olle Stål, L. Magnus Bäcklund, et al.. (2011). Pegylated liposomal doxorubicin as first-line monotherapy in elderly women with locally advanced or metastatic breast cancer: Novel treatment predictive factors identified. Cancer Letters. 313(2). 145–153. 19 indexed citations

Eriksson, Anna, Martin Höglund, Elin Lindhagen, et al.. (2010). Identification of AKN-032, a novel 2-aminopyrazine tyrosine kinase inhibitor, with significant preclinical activity in acute myeloid leukemia. Biochemical Pharmacology. 80(10). 1507–1516. 7 indexed citations

Haglund, Caroline, Anna Åleskog, Lena Håkansson, et al.. (2010). The FMCA-GM assays, high throughput non-clonogenic alternatives to CFU-GM in preclinical hematotoxicity testing. Toxicology Letters. 194(3). 102–107. 16 indexed citations

Mansouri, Mahmoud, Anna Åleskog, Mikael Jondal, et al.. (2009). IGHV3‐21 gene usage is associated with high TCL1 expression in chronic lymphocytic leukemia. European Journal Of Haematology. 84(2). 109–116. 9 indexed citations

Lindhagen, Elin, Meena Kanduri, Gerard Tobin, et al.. (2009). In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia – rolipram and prednisolone active in cells from patients with poor prognosis. European Journal Of Haematology. 83(1). 22–34. 4 indexed citations

Lindhagen, Elin, Anna Eriksson, Malin Wickström, et al.. (2008). Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia. European Journal Of Haematology. 81(5). 344–353. 28 indexed citations

Wiberg, Kristina, Kristina Carlson, Anna Åleskog, et al.. (2008). In vitro activity of bortezomib in cultures of patient tumour cells—potential utility in haematological malignancies. Medical Oncology. 26(2). 193–201. 16 indexed citations

Åleskog, Anna, Peter Nygren, Linda Rickardson, et al.. (2008). Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cellsin vitro, as single agent and in drug combination. Leukemia & lymphoma. 49(12). 2333–2343. 18 indexed citations

10.

Lindhagen, Elin, Linda Rickardson, Gary Elliott, et al.. (2007). Pharmacological profiling of novel non-COX-inhibiting indole-pyran analogues of etodolac reveals high solid tumour activity of SDX-308 in vitro. Investigational New Drugs. 25(4). 297–303. 7 indexed citations

11.

Norberg, Mona, Fiona Murray, Mats Merup, et al.. (2007). The BCL-2 promoter (−938C>A) polymorphism does not predict clinical outcome in chronic lymphocytic leukemia. Leukemia. 22(2). 339–343. 6 indexed citations

12.

Walsh, Sarah H., Pawel Grabowski, Mattias Berglund, et al.. (2007). Telomere length and correlation with histopathogenesis in B‐cell leukemias/lymphomas. European Journal Of Haematology. 78(4). 283–289. 11 indexed citations

13.

Olsson‐Strömberg, Ulla, Anna Åleskog, Martin Höglund, et al.. (2006). Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis. Anti-Cancer Drugs. 17(6). 631–639. 3 indexed citations

14.

Lindhagen, Elin, Lorenzo M. Leoni, Gary Elliott, et al.. (2006). R-etodolac (SDX-101) and the related indole–pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells. Cancer Chemotherapy and Pharmacology. 60(4). 545–553. 14 indexed citations

15.

Åleskog, Anna, et al.. (2005). In vitro activity of the flt3-inhibitor su5614 and standard cytotoxic agents in tumour cells from patients with wild type and mutated flt3 acute myeloid leukaemia. Leukemia Research. 29(9). 1079–1081. 7 indexed citations

16.

Grabowski, Pawel, Magnus Hultdin, Karin Karlsson, et al.. (2005). Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status. Blood. 105(12). 4807–4812. 90 indexed citations

17.

Forsman, Anna, Lars Rönnblom, Eva Baecklund, et al.. (2003). Single-tube nested quantitative PCR: a rational and sensitive technique for detection of retroviral DNA. Application to RERV-H/HRV-5 and confirmation of its rabbit origin. Journal of Virological Methods. 111(1). 1–11. 19 indexed citations

18.

Åleskog, Anna, Rolf Larsson, Peter Nygren, et al.. (2002). In vitro evaluation of the efficacy of idarubicin in human tumour cells from patients with low‐grade non‐Hodgkin's lymphoma. British Journal of Haematology. 117(3). 563–568. 8 indexed citations

19.

Åleskog, Anna, Jörgen Kristensen, Martin Höglund, et al.. (2001). Activity of CHS 828 in primary cultures of human hematological and solid tumors in vitro. Anti-Cancer Drugs. 12(10). 821–827. 15 indexed citations

20.

Åleskog, Anna, Rolf Larsson, Martin Höglund, Christer Sundström, & Jörgen Kristensen. (1999). Evaluation of purine and pyrimidine analogues in human tumor cells from patients with low‐grade lymphoproliferative disorders using the FMCA. European Journal Of Haematology. 62(5). 293–299. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact